Drug Maker Named In Investor Suit Over Diabetes Drug Candidate Misstatements
TRENTON, N.J. — A biopharmaceutical company violated federal securities laws by publicly misrepresenting the likelihood that its Type 1 diabetes treatment drug would gain U.S. Food and Drug Administration approval, which...To view the full article, register now.
Already a subscriber? Click here to view full article